Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
- 31 May 1995
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 98 (5) , 459-463
- https://doi.org/10.1016/s0002-9343(99)80345-3
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- INTERMITTENT CYCLICAL ETIDRONATE IN THE PREVENTION OF CORTICOSTEROID-INDUCED BONE LOSSRheumatology, 1994
- Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.Thorax, 1992
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Perspectives bone histomorphometry in glucocorticoid-induced osteoporosisJournal of Bone and Mineral Research, 1989
- PATHOGENESIS AND TREATMENT OF STEROID OSTEOPOROSISClinical Endocrinology, 1989
- PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD)The Lancet, 1988
- Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica.BMJ, 1986
- Quantitative computed tomography for prediction of vertebral fracture riskBone, 1985
- Steroid-Induced Fractures and Bone Loss in Patients with AsthmaNew England Journal of Medicine, 1983
- Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivoScience, 1969